In clinical trials1,2,4Evidence: Large human trialsMetabolic and weight · Heart and blood vessels

Efpeglenatide2

Also called HM11260C2

Key takeaway

Efpeglenatide is a GLP-1 receptor agonist built from an exendin-4 analogue joined, through a polyethylene glycol linker, to part of a human antibody (the IgG4 Fc fragment).2,3 In the AMPLITUDE-O trial of 4,076 adults with type 2 diabetes and heart or kidney disease, it lowered the rate of major cardiovascular events (7.0% versus 9.2% on placebo) and of kidney outcomes over about 1.8 years.3 No FDA approval is reported in the sources reviewed here, and it is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.2,4,6

Efpeglenatide at a glance

What it isAn exendin-4 analogue linked by polyethylene glycol to a human IgG4 Fc fragment, also coded HM11260C, according to FDA’s substance registry.2
FDA statusNot FDA-approved. No FDA approval is reported in the sources reviewed here, and a phase 3 trial in type 2 diabetes is registered as recruiting.1,2
Human evidenceOne large randomized, placebo-controlled cardiovascular outcomes trial, AMPLITUDE-O, in 4,076 adults with type 2 diabetes.3
Evidence strengthLarge randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned

What is efpeglenatide?

Efpeglenatide is a modified exendin-4, a GLP-1 receptor agonist peptide, attached by a polyethylene glycol linker to the Fc fragment of a human IgG4 antibody. FDA’s substance registry also lists the codes HM11260C and the name langlenatide.2

The AMPLITUDE-O report describes it as an exendin-based GLP-1 receptor agonist, structurally different from the GLP-1 drugs that resemble human GLP-1.3

How is efpeglenatide thought to work?

Like other GLP-1 receptor agonists it activates the GLP-1 receptor, which FDA’s substance registry records as its target.2

What do human studies show?

AMPLITUDE-O enrolled 4,076 adults with type 2 diabetes and either a history of cardiovascular disease or current kidney disease plus another risk factor, and randomly assigned them to efpeglenatide or placebo.3

Over a median of 1.81 years, a major cardiovascular event (heart attack, stroke or cardiovascular death) occurred in 7.0% of those on efpeglenatide and 9.2% on placebo, a hazard ratio of 0.73. A composite kidney outcome occurred in 13.0% and 18.4%.3

Diarrhoea, constipation, nausea, vomiting and bloating were more common with efpeglenatide than with placebo.3

What the evidence base contains

  • Large randomized human trial AMPLITUDE-O (NCT03496298): a randomized, placebo-controlled trial at 344 sites in 28 countries in 4,076 participants with type 2 diabetes and cardiovascular or kidney disease, in which major cardiovascular events occurred in 7.0% on efpeglenatide and 9.2% on placebo.3

Evidence-strength label: Large randomized human trials. How this label is assigned

Is efpeglenatide FDA-approved?

None of the sources reviewed here reports an approval of efpeglenatide by FDA.2,4

ClinicalTrials.gov lists a phase 3 trial of efpeglenatide in type 2 diabetes as recruiting in its May 13, 2026 record.1

FDA’s compounding safety-risk page, current as of April 22, 2026, does not list efpeglenatide.4

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Efpeglenatide is not among them.5,6

Timeline

  1. The AMPLITUDE-O trial of efpeglenatide in 4,076 adults with type 2 diabetes is published.3

What is still unknown?

Its effects beyond the AMPLITUDE-O population, which was limited to adults with type 2 diabetes at high cardiovascular or kidney risk.3

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Efpeglenatide: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Efpeglenatide are a bounded selection, not every registration or paper about Efpeglenatide. For the years before Efpeglenatide was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Efpeglenatide as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Efpeglenatide in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

In clinical trials; not FDA-approved. In AMPLITUDE-O, major cardiovascular events occurred in 7.0% of adults with type 2 diabetes on efpeglenatide and 9.2% on placebo. Efpeglenatide is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗↗

Status sources checked through November 14, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Efpeglenatide?

In clinical trials; not FDA-approved. In AMPLITUDE-O, major cardiovascular events occurred in 7.0% of adults with type 2 diabetes on efpeglenatide and 9.2% on placebo. Efpeglenatide is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗↗

The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
2
Source years
4
Drugs@FDA applications
0

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected regulatory records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Efpeglenatide?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

7Selected dated records
12Connected citations
4Populated source years2014–2026
2/4Record lanes present

Registered human studies

Trial composition

6 of 6 selected trial records include at least one phase value; 6 of 6 include a status value in the retained structured contract.

PhasesPhase 2 3Phase 3 2Phase 1 1
Status at observationCompleted 5Recruiting 1

PubMed bibliography

Publication composition

1 of 1 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
0
FDA Federal Register documents
0
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
7

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 7 dated records

Research hub

Explore the Efpeglenatide evidence record

Open all 7 records →
7Dated records
2Evidence types
7Cited public sources
4Source years

Change ledger

Recently changed for Efpeglenatide

Open all 7 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT01093729

PeptideScanner retained ClinicalTrials.gov record NCT01093729 at 2026-11-16T17:34:46.889Z. Its registry update date was 2014-02-07, and PeptideScanner's reviewed identity mapping was efpeglenatide.

PeptideScanner change date
November 16, 2026
Cited source date
February 7, 2014
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01452451

PeptideScanner retained ClinicalTrials.gov record NCT01452451 at 2026-11-16T17:34:46.889Z. Its registry update date was 2016-08-09, and PeptideScanner's reviewed identity mapping was efpeglenatide.

PeptideScanner change date
November 16, 2026
Cited source date
August 9, 2016
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT02075281

PeptideScanner retained ClinicalTrials.gov record NCT02075281 at 2026-11-16T17:34:46.889Z. Its registry update date was 2016-08-09, and PeptideScanner's reviewed identity mapping was efpeglenatide.

PeptideScanner change date
November 16, 2026
Cited source date
August 9, 2016
Evidence lane
Clinical trials

Official-source collections

Source records for Efpeglenatide

Open the full research atlas →
ClinicalTrials.gov6

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT06174779Registry update July 7, 2026 · completed at observation
  2. NCT07379333Registry update May 13, 2026 · current at observation
  3. NCT01452451Registry update August 9, 2016 · completed at observation
Explore all selected trial records →Explore all public record history →

Evidence types

Coverage by source year

Selected records span February 7, 2014 to July 7, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. Food and Drug Administration2,4
  • U.S. Department of Health and Human Services5
Dated updates connected to this profile · 7

Updates connected to this profile

Open the full cross-source timeline →
  1. Clinical trials

    ClinicalTrials.gov record NCT06174779↗

    PeptideScanner retained ClinicalTrials.gov record NCT06174779 at 2026-11-16T17:34:46.889Z. Its registry update date was 2026-07-07, and PeptideScanner's reviewed identity mapping was efpeglenatide.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT07379333↗

    PeptideScanner retained ClinicalTrials.gov record NCT07379333 at 2026-11-16T17:34:46.889Z. Its registry update date was 2026-05-13, and PeptideScanner's reviewed identity mapping was efpeglenatide.↗

  3. Literature metadata

    Population pharmacokinetics of efpeglenatide in individuals with obesity and with type 2 diabetes.↗

    PubMed lists PMID 41403449 in Frontiers in pharmacology as Journal Article, with publication-date metadata of 2025-12-01 (day precision). PeptideScanner associated the retained record with the identity slug efpeglenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT01452451↗

    PeptideScanner retained ClinicalTrials.gov record NCT01452451 at 2026-11-16T17:34:46.889Z. Its registry update date was 2016-08-09, and PeptideScanner's reviewed identity mapping was efpeglenatide.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT02075281↗

    PeptideScanner retained ClinicalTrials.gov record NCT02075281 at 2026-11-16T17:34:46.889Z. Its registry update date was 2016-08-09, and PeptideScanner's reviewed identity mapping was efpeglenatide.↗

  6. Clinical trials

    ClinicalTrials.gov record NCT02081118↗

    PeptideScanner retained ClinicalTrials.gov record NCT02081118 at 2026-11-16T17:34:46.889Z. Its registry update date was 2016-08-09, and PeptideScanner's reviewed identity mapping was efpeglenatide.↗

  7. Clinical trials

    ClinicalTrials.gov record NCT01093729↗

    PeptideScanner retained ClinicalTrials.gov record NCT01093729 at 2026-11-16T17:34:46.889Z. Its registry update date was 2014-02-07, and PeptideScanner's reviewed identity mapping was efpeglenatide.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    ClinicalTrials.gov record NCT07379333 · retained source version 2026-05-13:c599578eaa8d429e0152e13caf981fed9266ac8441a80524f20f68e1f1aaac63 ↗

    ClinicalTrials.gov · Official source · Source checked November 16, 2026

  2. 2
    Efpeglenatide substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 16, 2026

  3. 3
    Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes (2021) · PMID 34215025 ↗

    The New England Journal of Medicine · Official source · Source checked November 16, 2026

  4. 4
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  5. 5
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  6. 6
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026